{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:52:58Z","timestamp":1791604378542,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cllc.2026.08.003","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:31:34Z","timestamp":1786465894000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consolidative Hypofractionated Radiotherapy for Oligometastatic Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"Jongmoo","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Yup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Soo","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Ha","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Woo","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eung Bae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Young","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moonsik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong Kyung","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2026.08.003_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2026.08.003_bib0002","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (Version 4.2026). Plymouth Meeting, PA: National Comprehensive Cancer Network; 2026. Available from: https:\/\/www.nccn.org."},{"key":"10.1016\/j.cllc.2026.08.003_bib0003","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.08.003_bib0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/curroncol32020075","article-title":"Oligometastatic NSCLC: current perspectives and future challenges","volume":"32","author":"Torresan","year":"2025","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cllc.2026.08.003_bib0005","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/JTO.0b013e318262caf6","article-title":"Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450)","volume":"7","author":"De Ruysscher","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.08.003_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2026.08.003_bib0007","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2026.08.003_bib0008","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2026.08.003_bib0009","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2026.08.003_bib0010","article-title":"Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Reck","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2026.08.003_bib0011","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1200\/JCO.21.01719","article-title":"Practical management of oligometastatic non-small-cell lung cancer","volume":"40","author":"Jasper","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.08.003_bib0012","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of oligometastatic non-small cell lung cancer: an ASTRO\/ESTRO clinical practice guideline","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.cllc.2026.08.003_bib0013","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2026.08.003_bib0014","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ijrobp.2022.08.026","article-title":"Validation of the prognostic utility of ESTRO\/EORTC oligometastatic disease classification: a secondary analysis from the population-based Phase II SABR-5 trial","volume":"114","author":"Baker","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2026.08.003_bib0015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.radonc.2022.01.019","article-title":"Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: a retrospective single center study","volume":"168","author":"Willmann","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2026.08.003_bib0016","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.21873\/anticanres.14609","article-title":"Prognostic significance of oligometastatic disease classification by the ESTRO\/EORTC of cancer for patients with lung cancer treated with definitive radical radiotherapy","volume":"40","author":"Chen","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cllc.2026.08.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2012.03.009","article-title":"International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery","volume":"83","author":"Cox","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2026.08.003_bib0018","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.08.003_bib0019","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes","volume":"114","author":"Harrow","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2026.08.003_bib0020","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.3390\/cancers17152451","article-title":"Insights on oligometastatic non-small-cell lung cancer","volume":"17","author":"Valdivia","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2026.08.003_bib0021","article-title":"Definitive radiotherapy to the primary tumor in stage IV NSCLC: a consensus statement from the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee","volume":"21","author":"McMahon","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.08.003_bib0022","doi-asserted-by":"crossref","unstructured":"Iyengar P., Hu C., Gomez D.R., et al. NRG-LU002: Randomized Phase II\/III Trial of Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) plus Maintenance Systemic Therapy for Limited Metastatic Non-small Cell Lung Cancer (NSCLC). J Clin Oncol. 2024;42(16_suppl):8506.","DOI":"10.1200\/JCO.2024.42.16_suppl.8506"},{"key":"10.1016\/j.cllc.2026.08.003_bib0023","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3857\/roj.2025.00066","article-title":"Prognostic factors and risk stratification for survival in oligometastatic colorectal cancer treated with stereotactic body radiotherapy","volume":"43","author":"Kim","year":"2025","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.cllc.2026.08.003_bib0024","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.critrevonc.2018.06.005","article-title":"Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review","volume":"129","author":"Kobiela","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cllc.2026.08.003_bib0025","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/jso.25361","article-title":"Outcomes after hypofractionated stereotactic radiotherapy for colorectal cancer oligometastases","volume":"119","author":"Yu","year":"2019","journal-title":"J Surg Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:26:19Z","timestamp":1791602779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426001075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1525730426001075"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.08.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consolidative Hypofractionated Radiotherapy for Oligometastatic Non\u2013Small-Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}